NASDAQ : GALT
Galectin Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 334.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 334.82M |
| Enterprise Value | 465.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 100.85M |
| Shares Outstanding | 100.85M |
| Shares Change (YoY) | +3.55% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 46.98% |
| Owned by Institutions (%) | 15.87% |
| Float | 47.85M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.10 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.02 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -64.18% |
| Return on Invested Capital (ROIC) | -162.96% |
| Return on Capital Employed (ROCE) | 11.42% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.11M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -35.03% |
| 50-Day Moving Average | 3.81 |
| 200-Day Moving Average | 3.21 |
| Relative Strength Index (RSI) | 40.67 |
| Average Volume (20 Days) | 205,937 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.13M |
| Short Previous Month | 9.21M |
| Short % of Shares Out | 9.05% |
| Short % of Float | 19.08% |
| Short Ratio (days to cover) | 35.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.62M |
| Pretax Income | -27.84M |
| Net Income | -28.03M |
| EBITDA | n/a |
| EBIT | -15.62M |
| Earnings Per Share (EPS) | -$0.43 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 13.27M |
| Total Debt | 143.96M |
| Net Cash | -130.69M |
| Net Cash Per Share | -$1.30 |
| Equity (Book Value) | -136.85M |
| Book Value Per Share | -2.10 |
| Working Capital | -136.96M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 57,000 |
| Net Borrowing | 10.00M |
| Free Cash Flow | -15.89M |
| FCF Per Share | -$0.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.55% |
| Shareholder Yield | -3.55% |
| Earnings Yield | -12.96% |
| FCF Yield | -4.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 23, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |